Main patient characteristics in the whole cohort and according to post-RUX SPM occurrence
| . | All, n = 219 . | No SPM post-RUX, n = 201 . | SPM post-RUX, excluding NMSC, n = 9 . | NMSC post-RUX, n = 9 . |
|---|---|---|---|---|
| Sex, M/F | 129/90 | 116/85 | 6/3 | 7/2 |
| Median age at diagnosis (range), y | 62 (19-83) | 61 (19-83) | 62 (46-69) | 67 (35-73) |
| Diagnosis | ||||
| PMF | 99 | 90 | 6 | 3 |
| Post-ET MF | 37 | 34 | 2 | 1 |
| Post-PV MF | 83 | 77 | 1 | 5 |
| Mutational status | ||||
| JAK2 mutated | 160 | 147 | 4 | 9 |
| CALR mutated | 33 | 30 | 3 | 0 |
| MPL mutated | 5 | 4 | 1 | 0 |
| Triple negative | 7 | 6 | 1 | 0 |
| Comutated | 3 | 3 | 0 | 0 |
| NA* | 11 | 11 | 0 | 0 |
| IPSS score at diagnosis (for PMF patients only, available in 89) | ||||
| Low | 27 | 26 | 1 | 0 |
| Intermediate-1 | 20 | 18 | 0 | 2 |
| Intermediate-2 | 22 | 19 | 2 | 1 |
| High | 20 | 19 | 1 | 0 |
| MYSEC-PM score at diagnosis (for SMF patients only, available in 107) | ||||
| Low | 26 | 25 | 1 | 0 |
| Intermediate-1 | 54 | 48 | 1 | 5 |
| Intermediate-2 | 20 | 18 | 1 | 1 |
| High | 7 | 7 | 0 | 0 |
| Median time from diagnosis to RUX start (range), mo | 30 (0-294) | 30 (0-294) | 30 (8-149) | 38 (1-59) |
| At RUX start | ||||
| Median age (range), y | 66 (24-84) | 65 (24-84) | 67 (49-74) | 70 (67-78) |
| Median WBC (range), ×109/L | 11.0 (1.8-70.0) | 11.1 (1.8-70.0) | 12.9 (5.3-31.1) | 10.3 (4.2-23.3) |
| Median Hb (range), g/dL | 10.4 (5.8-16.0) | 10.4 (5.8-16.0) | 10.0 (8.8-12.4) | 11.1 (8.9-13.5) |
| Median PLT (range), ×109/L | 213 (14-1425) | 212 (14-1425) | 387 (75-503) | 249 (61-570) |
| Median peripheral blood blasts (range), % | 1 (0-12) | 1 (0-12) | 2 (0-6) | 1 (0-6) |
| Constitutional symptoms, absent/present/NA | 72/141/6 | 67/129/5 | 2/7/0 | 3/5/1 |
| Median palpable splenomegaly from lcm (range), cm | 10.0 (0.0-34.0) | 10.0 (0.0-34.0) | 9.5 (5.0-24.0) | 10.0 (5.0-19.0) |
| DIPSS score, for PMF patients only, available in 95 | ||||
| Low | 3 | 3 | 0 | 0 |
| Intermediate-1 | 36 | 36 | 0 | 0 |
| Intermediate-2 | 41 | 34 | 5 | 2 |
| High | 15 | 13 | 1 | 1 |
| Median follow-up after RUX start (range), mo | 24 (0-110) | 23 (0-110) | 31 (12-75) | 39 (7-56) |
| Median RUX exposure (range), mo | 18 (0-110) | 17 (0-110) | 31 (12-75) | 39 (7-56) |
| SPM pre-RUX, all types | 20 | 16 | 3 | 1 |
| SPM pre-RUX, excluding NMSC | 16 | 14 | 2 | 0 |
| . | All, n = 219 . | No SPM post-RUX, n = 201 . | SPM post-RUX, excluding NMSC, n = 9 . | NMSC post-RUX, n = 9 . |
|---|---|---|---|---|
| Sex, M/F | 129/90 | 116/85 | 6/3 | 7/2 |
| Median age at diagnosis (range), y | 62 (19-83) | 61 (19-83) | 62 (46-69) | 67 (35-73) |
| Diagnosis | ||||
| PMF | 99 | 90 | 6 | 3 |
| Post-ET MF | 37 | 34 | 2 | 1 |
| Post-PV MF | 83 | 77 | 1 | 5 |
| Mutational status | ||||
| JAK2 mutated | 160 | 147 | 4 | 9 |
| CALR mutated | 33 | 30 | 3 | 0 |
| MPL mutated | 5 | 4 | 1 | 0 |
| Triple negative | 7 | 6 | 1 | 0 |
| Comutated | 3 | 3 | 0 | 0 |
| NA* | 11 | 11 | 0 | 0 |
| IPSS score at diagnosis (for PMF patients only, available in 89) | ||||
| Low | 27 | 26 | 1 | 0 |
| Intermediate-1 | 20 | 18 | 0 | 2 |
| Intermediate-2 | 22 | 19 | 2 | 1 |
| High | 20 | 19 | 1 | 0 |
| MYSEC-PM score at diagnosis (for SMF patients only, available in 107) | ||||
| Low | 26 | 25 | 1 | 0 |
| Intermediate-1 | 54 | 48 | 1 | 5 |
| Intermediate-2 | 20 | 18 | 1 | 1 |
| High | 7 | 7 | 0 | 0 |
| Median time from diagnosis to RUX start (range), mo | 30 (0-294) | 30 (0-294) | 30 (8-149) | 38 (1-59) |
| At RUX start | ||||
| Median age (range), y | 66 (24-84) | 65 (24-84) | 67 (49-74) | 70 (67-78) |
| Median WBC (range), ×109/L | 11.0 (1.8-70.0) | 11.1 (1.8-70.0) | 12.9 (5.3-31.1) | 10.3 (4.2-23.3) |
| Median Hb (range), g/dL | 10.4 (5.8-16.0) | 10.4 (5.8-16.0) | 10.0 (8.8-12.4) | 11.1 (8.9-13.5) |
| Median PLT (range), ×109/L | 213 (14-1425) | 212 (14-1425) | 387 (75-503) | 249 (61-570) |
| Median peripheral blood blasts (range), % | 1 (0-12) | 1 (0-12) | 2 (0-6) | 1 (0-6) |
| Constitutional symptoms, absent/present/NA | 72/141/6 | 67/129/5 | 2/7/0 | 3/5/1 |
| Median palpable splenomegaly from lcm (range), cm | 10.0 (0.0-34.0) | 10.0 (0.0-34.0) | 9.5 (5.0-24.0) | 10.0 (5.0-19.0) |
| DIPSS score, for PMF patients only, available in 95 | ||||
| Low | 3 | 3 | 0 | 0 |
| Intermediate-1 | 36 | 36 | 0 | 0 |
| Intermediate-2 | 41 | 34 | 5 | 2 |
| High | 15 | 13 | 1 | 1 |
| Median follow-up after RUX start (range), mo | 24 (0-110) | 23 (0-110) | 31 (12-75) | 39 (7-56) |
| Median RUX exposure (range), mo | 18 (0-110) | 17 (0-110) | 31 (12-75) | 39 (7-56) |
| SPM pre-RUX, all types | 20 | 16 | 3 | 1 |
| SPM pre-RUX, excluding NMSC | 16 | 14 | 2 | 0 |
DIPSS, Dynamic International Prognostic Scoring System; ET, essential thrombocythemia; F, female; Hb, hemoglobin; IPSS, International Prognostic Scoring System; lcm, left costal margin; M, male; MF, myelofibrosis; MYSEC-PM, Myelofibrosis Secondary to PV and ET–Prognostic Model; NA, not available; NMSC, nonmelanoma skin cancer; PLT, platelet; PMF, primary myelofibrosis; PV, polycythemia vera; RUX, ruxolitinib; SMF, secondary myelofibrosis; SPM, second primary malignancy; WBC, white blood cell.
NA includes patients who have tested 1 or 2 driver mutations and resulted unmutated but cannot be defined "triple negative" (TN) because not all 3 driver mutations have been studied, and patients for whom the driver mutational status is not available.